<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401973</url>
  </required_header>
  <id_info>
    <org_study_id>10768</org_study_id>
    <secondary_id>F1D-US-HGMM</secondary_id>
    <nct_id>NCT00401973</nct_id>
  </id_info>
  <brief_title>Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine</brief_title>
  <official_title>The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The goal of this study is to answer the following questions:

        -  Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the
           weight gain that is associated with olanzapine

        -  Whether taking amantadine, metformin or zonisamide can help patients decrease or
           eliminate some of the changes in body that occur with weight gain

        -  How weight gain associated with olanzapine can affect people

        -  Whether treatment with amantadine, metformin or zonisamide can help eliminate weight
           gain associated with olanzapine and not interfere with the positive effects of
           olanzapine on functioning of people with schizophrenia and other diseases
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint in Weight</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Endpoint in Fasting Triglycerides</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Endpoint in Fasting Total Cholesterol</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Endpoint in Fasting Glucose</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Endpoint in Hemoglobin A1c</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks</measure>
    <time_frame>Baseline to endpoint (22 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorders</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine plus behavioral information</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine + Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>5-20 milligrams (mg), oral, daily for 22 weeks.</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Olanzapine + Amantadine</arm_group_label>
    <arm_group_label>Olanzapine + Metformin</arm_group_label>
    <other_name>LY170053</other_name>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amantadine</intervention_name>
    <description>Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.</description>
    <arm_group_label>Olanzapine + Amantadine</arm_group_label>
    <arm_group_label>Olanzapine + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.</description>
    <arm_group_label>Olanzapine + Amantadine</arm_group_label>
    <arm_group_label>Olanzapine + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zonisamide</intervention_name>
    <description>Zonisamide, 100-400mg, oral, daily.</description>
    <arm_group_label>Olanzapine + Amantadine</arm_group_label>
    <arm_group_label>Olanzapine + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Wellness education</intervention_name>
    <description>weight management</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Olanzapine + Amantadine</arm_group_label>
    <arm_group_label>Olanzapine + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You must have been diagnosed with schizophrenia or schizoaffective disorder

          -  You must be able to visit the doctor's office once every two weeks for three months,
             then once every four weeks for the next three months with a possible bi-weekly visit
             during the fifth month

          -  If you are currently taking a medication for schizophrenia or schizoaffective
             disorder, you have been taking it for at least 30 days without any changes

          -  If you are a female, you must have a negative pregnancy test and be using an effective
             method of contraception

        Exclusion Criteria:

          -  You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level
             (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack,
             stroke, uncontrolled seizures, serious infection, unstable heart disease (such as
             ischemic heart disease or congestive heart failure), an uncorrected narrow angle
             glaucoma or human immunodeficiency virus (HIV)

          -  You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine
             systems, or blood

          -  You have a diagnosis of an eating disorder

          -  You have a history of Parkinson's Disease or any related disorders

          -  You are allergic to sulfa drugs or any of the medications involved in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21020-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salvador</city>
        <zip>40301500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beer Yaacov</city>
        <zip>70350</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>143-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>117603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>August 27, 2009</results_first_submitted>
  <results_first_submitted_qc>August 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2009</results_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine + Amantadine</title>
          <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
        </group>
        <group group_id="P3">
          <title>Olanzapine + Metformin</title>
          <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Olanzapine + Amantadine</title>
          <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
        </group>
        <group group_id="B3">
          <title>Olanzapine + Metformin</title>
          <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="12.89"/>
                    <measurement group_id="B2" value="38.2" spread="11.40"/>
                    <measurement group_id="B3" value="38.7" spread="12.01"/>
                    <measurement group_id="B4" value="38.5" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Schizoaffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizophrenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms/square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="4.53"/>
                    <measurement group_id="B2" value="27.3" spread="4.67"/>
                    <measurement group_id="B3" value="27.0" spread="4.84"/>
                    <measurement group_id="B4" value="27.1" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Onset Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.35" spread="8.42"/>
                    <measurement group_id="B2" value="26.44" spread="9.98"/>
                    <measurement group_id="B3" value="24.40" spread="9.18"/>
                    <measurement group_id="B4" value="25.15" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Number of Episodes</title>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.53" spread="1.02"/>
                    <measurement group_id="B2" value="2.19" spread="5.90"/>
                    <measurement group_id="B3" value="2.22" spread="5.77"/>
                    <measurement group_id="B4" value="2.04" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.0" spread="16.33"/>
                    <measurement group_id="B2" value="79.1" spread="17.27"/>
                    <measurement group_id="B3" value="76.2" spread="16.22"/>
                    <measurement group_id="B4" value="77.5" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint in Weight</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>All randomized participants with baseline and at least one postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Weight</title>
          <population>All randomized participants with baseline and at least one postbaseline measurement.</population>
          <units>kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="0.75"/>
                    <measurement group_id="O2" value="2.40" spread="0.65"/>
                    <measurement group_id="O3" value="0.65" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To detect a difference between treatment arms of 3.06 kg in mean weight change from baseline to endpoint, 150 patients must be enrolled in stepped intervention arm and 50 in control arm. Assuming a standard deviation of 6.87 kg, there is 80% power to detect a difference between treatment arms on a 1-sided 2-sample t-test at the 5% significance level. Primary analysis was the comparison of mean weight change for 'olanzapine only' versus pooled 'olanzapine &amp; adjunctive treatment' arm at Week 22.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>P-value for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures Analysis</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis=weight gain associated with olanzapine can be prevented or mitigated with an adjunctive pharmacological algorithm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures Analysis</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures Analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Endpoint in Fasting Triglycerides</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Endpoint in Fasting Triglycerides</title>
          <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.81"/>
                    <measurement group_id="O2" value="1.61" spread="0.76"/>
                    <measurement group_id="O3" value="1.68" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1.01"/>
                    <measurement group_id="O2" value="0.35" spread="0.88"/>
                    <measurement group_id="O3" value="0.06" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.498</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.637</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Endpoint in Fasting Total Cholesterol</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Endpoint in Fasting Total Cholesterol</title>
          <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
          <units>millimole per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="1.00"/>
                    <measurement group_id="O2" value="5.03" spread="1.09"/>
                    <measurement group_id="O3" value="4.91" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.84"/>
                    <measurement group_id="O2" value="0.01" spread="1.06"/>
                    <measurement group_id="O3" value="-0.08" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>Number of randomized participants with a baseline and at least one post-baseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol</title>
          <population>Number of randomized participants with a baseline and at least one post-baseline measurement. Last post-baseline measurement carried forward.</population>
          <units>millimole per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.29"/>
                    <measurement group_id="O2" value="1.26" spread="0.36"/>
                    <measurement group_id="O3" value="1.22" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.23"/>
                    <measurement group_id="O2" value="-0.11" spread="0.25"/>
                    <measurement group_id="O3" value="-0.08" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol</title>
          <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
          <units>millimole per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="0.88"/>
                    <measurement group_id="O2" value="3.06" spread="1.03"/>
                    <measurement group_id="O3" value="2.91" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.60"/>
                    <measurement group_id="O2" value="-0.04" spread="0.95"/>
                    <measurement group_id="O3" value="-0.02" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.152</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Endpoint in Fasting Glucose</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Endpoint in Fasting Glucose</title>
          <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
          <units>millimole per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" spread="0.46"/>
                    <measurement group_id="O2" value="5.25" spread="0.78"/>
                    <measurement group_id="O3" value="5.28" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.99"/>
                    <measurement group_id="O2" value="0.10" spread="0.48"/>
                    <measurement group_id="O3" value="0.01" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.499</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.833</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.339</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Endpoint in Hemoglobin A1c</title>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Endpoint in Hemoglobin A1c</title>
          <population>All randomized participants with baseline and at least one postbaseline measurement. Last post-baseline measurement carried forward.</population>
          <units>percent hemoglobin A1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="0.46"/>
                    <measurement group_id="O2" value="5.48" spread="0.39"/>
                    <measurement group_id="O3" value="5.53" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.45"/>
                    <measurement group_id="O2" value="0.10" spread="0.37"/>
                    <measurement group_id="O3" value="-0.03" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.278</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.976</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score</title>
        <description>The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.</description>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>Number of participants with a baseline and at least one post baseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score</title>
          <description>The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.</description>
          <population>Number of participants with a baseline and at least one post baseline measurement. Last post-baseline measurement carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.24" spread="15.98"/>
                    <measurement group_id="O2" value="45.90" spread="12.44"/>
                    <measurement group_id="O3" value="47.00" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.89" spread="18.61"/>
                    <measurement group_id="O2" value="-9.90" spread="11.24"/>
                    <measurement group_id="O3" value="-9.72" spread="14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.225</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>Number of participants with a baseline and at least one post baseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <population>Number of participants with a baseline and at least one post baseline measurement. Last post-baseline measurement carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.76" spread="8.08"/>
                    <measurement group_id="O2" value="14.22" spread="11.14"/>
                    <measurement group_id="O3" value="15.40" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.39" spread="8.37"/>
                    <measurement group_id="O2" value="-4.12" spread="7.20"/>
                    <measurement group_id="O3" value="-4.36" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <p_value_desc>P-value for Change from Baseline</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)</title>
        <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>Number of participants with a baseline and at least one post baseline measurement. Last post-baseline measurement carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine + Amantadine</title>
            <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine + Metformin</title>
            <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)</title>
          <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
          <population>Number of participants with a baseline and at least one post baseline measurement. Last post-baseline measurement carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="1.24"/>
                    <measurement group_id="O2" value="4.03" spread="1.07"/>
                    <measurement group_id="O3" value="4.00" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="1.13"/>
                    <measurement group_id="O2" value="-0.72" spread="1.14"/>
                    <measurement group_id="O3" value="-0.79" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.474</p_value>
            <p_value_desc>P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.404</p_value>
            <p_value_desc>P-value for Change from Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.652</p_value>
            <p_value_desc>P-value for Change from Baseline</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks</title>
        <description>To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.</description>
        <time_frame>Baseline to endpoint (22 weeks)</time_frame>
        <population>N=Pairs of Observations for the combined treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Weeks</title>
            <description>Combined treatment groups:
olanzapine plus behavioral information [olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks].
Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information [olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms)].
Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information [olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms)].</description>
          </group>
          <group group_id="O2">
            <title>22 Weeks</title>
            <description>Combined treatment groups:
olanzapine plus behavioral information [olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks].
Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information [olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms)].
Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information [olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms)].</description>
          </group>
        </group_list>
        <measure>
          <title>Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks</title>
          <description>To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.</description>
          <population>N=Pairs of Observations for the combined treatment groups.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EI: Disinhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034"/>
                    <measurement group_id="O2" value="0.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EI: Cognitive Restraint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.273"/>
                    <measurement group_id="O2" value="-0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EI: Hunger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.150"/>
                    <measurement group_id="O2" value="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCI: Carbohydrates/Starches (N=186, N=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="-0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCI: Fast Food Fats (N=188, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019"/>
                    <measurement group_id="O2" value="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCI: High Fats (N=186, N=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051"/>
                    <measurement group_id="O2" value="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCI: Sweets (N=187, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022"/>
                    <measurement group_id="O2" value="-0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCI: Total Score (N=184, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039"/>
                    <measurement group_id="O2" value="-0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>olanzapine plus behavioral information. olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Olanzapine + Amantadine</title>
          <description>Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. amantadine: 100 mg, oral, twice a day. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
        </group>
        <group group_id="E3">
          <title>Olanzapine + Metformin</title>
          <description>Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information.
olanzapine: 5-20 milligrams (mg), oral, daily for 22 weeks. metformin: 500 mg, oral, twice a day for 2 weeks, titrated to 500 mg three times a day thereafter. zonisamide: 100-400 mg, oral, daily (only if patient gained greater than 3 kilograms).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
                <counts group_id="E2" subjects_affected="4"/>
                <counts group_id="E3" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26"/>
                <counts group_id="E2" subjects_affected="38"/>
                <counts group_id="E3" subjects_affected="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

